Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome | Zendy

April Zhang | Zendy; Sabine Duchatelet | Zendy; Nikita Lakdawala | Zendy; Richard L. Tower | Zendy; Carrie Diamond | Zendy; Kalyani Marathe | Zendy; India Hill | Zendy; Gabriele Richard | Zendy; Yaser Diab | Zendy; A. Yasmine Kirkorian | Zendy; Flora Mitie Watanabe | Zendy; Dawn H. Siegel | Zendy; Alain Hovnanian | Zendy

Open Access

Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome

Author(s) -

April Zhang,

Sabine Duchatelet,

Nikita Lakdawala,

Richard L. Tower,

Carrie Diamond,

Kalyani Marathe,

India Hill,

Gabriele Richard,

Yaser Diab,

A. Yasmine Kirkorian,

Flora Mitie Watanabe,

Dawn H. Siegel,

Alain Hovnanian

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2019.4141

Subject(s) - medicine , erlotinib , sirolimus , epidermal growth factor receptor , outpatient clinic , ribosomal protein s6 , dermatology life quality index , erlotinib hydrochloride , pi3k/akt/mtor pathway , oncology , cancer , signal transduction , biochemistry , chemistry , disease , p70 s6 kinase 1

Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research